DermTech has patented a method for non-invasively identifying non-melanoma skin cancer (NMSC) by isolating nucleic acids from a skin sample, detecting gene expression levels of specific genes, and performing surgery if NMSC is detected. This innovative approach could revolutionize skin cancer diagnosis and treatment. GlobalData’s report on DermTech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on DermTech, Predictive cancer diagnosis models was a key innovation area identified from patents. DermTech's grant share as of May 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Non-invasive method for identifying non-melanoma skin cancer
A recently granted patent (Publication Number: US11976332B2) outlines a method for non-invasively identifying non-melanoma skin cancers (NMSC) such as basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). The method involves isolating nucleic acids from a skin sample obtained from a subject suspected of having NMSC, then contacting these nucleic acids with a set of probes that recognize specific genes of interest. By detecting the binding between these genes and the probes, the subject can be identified as having NMSC based on the presence or amount of binding. Subsequently, surgery is performed to remove or partially remove the NMSC from the subject.
Furthermore, the patent details additional steps such as repeating the process for multiple skin samples, differentiating between cancerous and non-cancerous skin samples, and analyzing pair-wise interactions between genes of interest to determine the presence of NMSC. The method also includes providing information on disease state identification, treatment success likelihood, disease progression, and disease stage identification. By comparing the binding of genes of interest to a control amount, the subject can be identified as having BCC or SCC, leading to the administration of a therapeutic agent and subsequent surgery. Overall, the method aims to accurately identify NMSC non-invasively and guide appropriate treatment decisions for subjects with BCC or SCC.
To know more about GlobalData’s detailed insights on DermTech, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
